Genetics and Precision Medicine with Hematologic Diseases in Children

A special issue of Children (ISSN 2227-9067). This special issue belongs to the section "Pediatric Hematology & Oncology".

Deadline for manuscript submissions: 1 February 2026 | Viewed by 740

Special Issue Editor


E-Mail Website
Guest Editor
Department of Clinical Hematology-Blood Bank and Hemostasis, Onassis Cardiac Surgery Centre, 176 74 Kallithea, Greece
Interests: hemophilia/thrombosis; laboratory hematology; genetics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Hematologic diseases in children embrace both malignant and non-malignant conditions that are unique to children, or otherwise are hematologic disorders which are also found in adolescents and adults but require a different, age-related approach.

The role of genetics has been extensively studied in inherited hematologic disorders such as hemoglobinopathies and hemophilia. However, many genetic disorders and syndromes express hematologic manifestations and (epi)genetics also play an important role in malignant hematology. In the era of gene therapy and precision medicine, a better understanding of the genetic background is fundamental.

This Special Issue is intended to encourage and improve communication and collaboration between pediatric and adult hematology and promote a multidisciplinary approach with other clinical specialties.

Researchers and physicians are encouraged to share their findings and experience in order to improve knowledge regarding major advances in the diagnosis and treatment of hematologic diseases in children. Contributors are invited to send original research articles, systematic reviews, meta-analyses, and case-based reviews.

I look forward to receiving your contributions.

Dr. Theoni Kanellopoulou
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Children is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • children
  • genetics
  • hematologic diseases
  • hemostasis/thrombosis
  • immunodeficiency
  • laboratory hematology
  • leukemia/lymphoma
  • non-malignant hematology
  • sickle cell disease/thalassemia

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

15 pages, 218 KiB  
Article
Patient-Reported Disease Presentation, Interventions, and Outcomes in United States Pregnancies Affected by Alloimmunization at Risk of Hemolytic Disease of the Fetus and Newborn
by Molly R. Sherwood, Bethany M. Weathersby, Marion E. Granger Howard and Kara B. Markham
Children 2025, 12(7), 822; https://doi.org/10.3390/children12070822 - 22 Jun 2025
Viewed by 473
Abstract
Background/Objectives: Pregnancies complicated by red cell alloimmunization can progress to hemolytic disease of the fetus and newborn (HDFN), requiring close monitoring and timely intervention to prevent fetal/neonatal morbidity and mortality. This study investigated disease presentation, interventions, and outcomes in respondents with a history [...] Read more.
Background/Objectives: Pregnancies complicated by red cell alloimmunization can progress to hemolytic disease of the fetus and newborn (HDFN), requiring close monitoring and timely intervention to prevent fetal/neonatal morbidity and mortality. This study investigated disease presentation, interventions, and outcomes in respondents with a history of alloimmunized pregnancy. Methods: This was a retrospective cross-sectional survey study administered online to alloimmunized patients between November 2022–February 2023. A total of 127 participants reported on 200 alloimmunized pregnancies. Distribution of pregnancy characteristics, antibodies and titers, monitoring, treatments and fetal outcomes were described and stratified where appropriate by fetal antigen status and disease severity. Outcomes and management practices in subsequent pregnancies following fetal loss to HDFN are reported. Results: Multiple antibodies were present in 42% of pregnancies with known antibody type (80/192). Titers reached critical levels (any titer for Anti-K; ≥16 for all other antibodies) in 71% (125/176) of pregnancies where titer was reported. Among fetal antigen positive pregnancies with critical titers, intrauterine transfusions were conducted in 40% (42/106), intravenous immunoglobulin was administered in 14% (15/106), plasmapheresis in 7% (7/106), and phenobarbital in 9% (9/106). Complications from transfusion were reported in 38% of pregnancies receiving intrauterine transfusion (17/45). Fetal death due to HDFN or complications from intrauterine transfusion was reported in 9% of antigen positive pregnancies with critical titers (10/106) and 16% of pregnancies receiving intrauterine transfusion (7/45). Conclusions: Disease presentation and severity complements previous research in this disease population, however, monitoring practices were diverse. Fetal death and intrauterine complication rates were higher than those previously reported in large international referral centers. Development of best practices and centralized referral centers may improve disease outcomes. Full article
(This article belongs to the Special Issue Genetics and Precision Medicine with Hematologic Diseases in Children)
Back to TopTop